Therapeutic Administration of Mesenchymal Stem Cells Abrogates the Relapse Phase in Chronic Relapsing-Remitting EAE

@inproceedings{Scuteri2015TherapeuticAO,
  title={Therapeutic Administration of Mesenchymal Stem Cells Abrogates the Relapse Phase in Chronic Relapsing-Remitting EAE},
  author={Arianna Scuteri and Elisabetta Donzelli and R Rigolio and Elisa Ballarini and Marianna Monfrini and Luca Crippa and Alessia Chiorazzi and Valentina Alda Carozzi and Cristina Meregalli and Annalisa Canta and Norberto Oggioni and Giovanni Tredici and Guido Cavaletti},
  year={2015}
}
Multiple Sclerosis (MS) is a neuroinflammatory and immune-mediated chronic disease of the Central Nervous System which progressively damages the axonal myelin sheath, leading to axonal transmission impairment and to the development of neurological symptoms. Most MS cases are characterized by a relapsing-remitting course, and current therapies rely only on the use of immunomodulating drugs which are, however, unable to reverse disease progression. Among the newly proposed alternative therapies… CONTINUE READING

Similar Papers

Figures and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Experimental autoimmune encephalomyelitis in the rat.

  • Current protocols in immunology
  • 2001
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

12-19

A Scuteri, M Ravasi, S Pasini, M Bossi, 172 Tredici G Mesenchymal stem cells support dorsal ro Neuroscience
  • [PubMed] Citation: Scuteri A, Donzelli E, Rigolio R, Ballarini E, Monfrini M, et al.
  • 2015
VIEW 1 EXCERPT

Mesenchymal stem cell transplantation in multiple sclerosis

JA Cohen
  • J Neurol Sci
  • 2013
VIEW 1 EXCERPT